Blog

Secure, scalable, multi-cloud platform using federated learning aims to accelerate cancer discoveries and treatments

SEATTLE, WASHINGTON / ACCESS Newswire / October 1, 2025 / The Cancer AI Alliance (CAIA) – a research collaboration of top cancer centers – today announced the first scalable platform using federated learning for cancer research.

CAIA is comprised of National Cancer Institute-designated cancer centers Dana-Farber Cancer Institute, Fred Hutch Cancer Center, Memorial Sloan Kettering Cancer Center, and The Sidney Kimmel Comprehensive Cancer Center and Whiting School of Engineering at Johns Hopkins with financial and technical support from technology industry leaders Amazon Web Services (AWS), Deloitte, Ai2 (Allen Institute for AI), Google, Microsoft, NVIDIA and Slalom.

The platform serves as the technological foundation of CAIA’s aim to save more lives by enabling researchers and clinicians to train AI models that learn from participating cancer centers’ millions of clinical data points while maintaining data security, privacy and adherence to regulatory and ethical standards.

“We are at an urgent inflection point in both cancer research and AI, and this platform enables us to rise to this moment by rapidly advancing cancer research, treatments and care,” said Jeff Leek, PhD, vice president and chief data officer at Fred Hutch and holder of the J. Orin Edson Foundation Endowed Chair.

“Currently, it takes years to uncover new insights that can be translated into better treatments and care, but this platform will accelerate the pace of breakthrough discoveries by up to tenfold, reducing that time from years to months,” said Leek, who is also the founder and scientific director of CAIA and a member of its steering committee.

“It cannot be overstated how momentous it is that we came together to launch this platform in just one year, and we did it as a unified alliance with a shared mission to eradicate cancer,” said Brian M. Bot, director of the strategic coordinating center for CAIA.

While federated learning – a machine learning method that preserves anonymity of individual data – has been gaining steam for nearly 10 years, adapting the technology for multi-institution use in cancer research has proved elusive due to significant technological, regulatory, patient privacy and data harmonization challenges, as well as the coordination effort necessary to bring together organizations of this scale and complexity.

Development of CAIA’s platform was possible due to an intense focus on collaboration and a drive for collective action across the participating cancer centers and technology companies, resulting in a unified technical, legal and governance structure.

“CAIA represents a strategic shift leveraging collective strength rather than isolation,” said Anaeze Offodile, MD, MPH, chief strategy officer of Memorial Sloan Kettering Cancer Center. “By combining MSK’s clinical expertise with the alliance’s capital, network of technology partners, data and federated framework, we can accelerate meaningful advances in cancer care while upholding the highest standards of security and integrity. Together, we move closer to the shared goal of reducing-and ultimately eliminating-the burden of cancer.”

The federated learning platform works like this: participating cancer centers implement federated learning technology at their institutions, each connecting to a centralized orchestration component of the platform. Using this architecture, AI models travel to each participating cancer center’s secure data to learn from it locally, generating a summary of its learnings without individual clinical data ever leaving institutional firewalls. The insights gained from training the model on each cancer center’s de-identified data are then aggregated centrally to strengthen the AI models to uncover patterns, maximizing the value of the collective knowledge base.

Enabling researchers to develop models on data from multiple cancer centers through a collaborative, federated learning ecosystem creates a paradigm shift from solving problems in isolation to solving them together. More importantly, these updated AI models could significantly improve health outcomes for cancer patients by revealing trends across more diverse populations and rare cancers.

“CAIA will enable unprecedented exploration of AI models for cancer patient data, through a privacy-aware technical framework and a collaborative research alliance,” said Alexis Battle, PhD, professor of biomedical engineering and computer science, and director of the Malone Center for Engineering in Healthcare, and director for Research Strategy and Partnerships, Data Science and AI Institute at the Johns Hopkins Whiting School of Engineering.

“This could serve as a model for every cancer center in the country to join CAIA in this collaborative effort to unlock innovation in cancer care,” continued Vasan Yegnasubramanian, MD, PhD, professor of oncology, pathology, and radiation oncology and molecular radiation sciences at the Johns Hopkins Kimmel Cancer Center and director of inHealth Precision Medicine at Johns Hopkins Medicine. Battle and Yegnasubramanian are members of the steering committee for CAIA.

Eight unique projects are being launched by researchers across the participating cancer centers. These initial projects aim to tackle some of oncology’s most persistent challenges, from predicting treatment response to identifying novel biomarkers and analyzing rare cancer trends. The projects use the federated learning platform and structured, de-identified data housed securely by participating cancer centers, which collectively provides a diverse and representative foundation of over 1 million patients for modeling and analysis.

The platform’s true power, however, lies in its potential to scale up. Over the next year, CAIA plans to enable dozens of research models and add more participants to the alliance.

“With the launch of CAIA we have laid a critical foundation in the effort to accelerate new discoveries and the combined data from our cancer centers can now power these innovative AI models. We are excited to share these models with research centers across the nation and exponentially expand access to the data that will drive progress toward better diagnosis, treatment and outcomes for cancer patients everywhere,” said Eliezer Van Allen, MD, Chandra Nohria Family Chair for AI in Cancer Research at Dana-Farber Cancer Institute.

# # #

Additional CAIA collaborator quotes

“AWS is immensely proud to help power this industry-first collaboration with our cloud technology and LLM platforms, in support of CAIA’s mission to transform cancer research and care,” said Dr. Angela Shippy, Senior Physician Executive and Clinical Innovation Lead at Amazon Web Services. “Collaboration often leads to discovery, and I’m eager to see what medical breakthroughs come from the collective expertise of these world-class cancer centers and global technology leaders.”

“At Deloitte, we believe collaboration drives progress,” said Jason Girzadas, CEO of Deloitte US. “CAIA brings together leaders across industries to address one of the world’s most critical health challenges. The unprecedented speed of developing and delivering CAIA’s platform is made possible through each individual group driving toward this common goal, and Deloitte is proud to bring AI and strategy expertise to the Alliance.”

“We are proud to be part of this effort to bring the power of AI to the complex problem of cancer research,” said Ali Farhadi, CEO of Ai2. “CAIA’s ability to bring together cancer centers in a collaborative effort with our state of the art AI tools is a powerful combination that will accelerate scientific progress and save lives. It’s been incredible to see our tools in the hands of oncologists and researchers, where their early efforts have already demonstrated incredible potential to unlock discoveries that could reshape healthcare and deliver life-changing outcomes for patients.”

“Google is honored to continue to partner with the Cancer AI Alliance,” said Reymund Dumlao, Director, State and Local Government and Education, Google Public Sector. “This groundbreaking initiative represents a pivotal moment in our collective pursuit to eradicate cancer. By integrating advanced federated AI technologies with the expertise and data resources of leading cancer centers, we are establishing a secure, scalable platform designed to accelerate scientific discovery. This collaborative ecosystem will enable a unified effort against cancer, transforming research methods and expediting the delivery of innovative treatments to patients globally.”

“The collaborative work that CAIA has done will revolutionize how medical research is done, accelerate scientific discovery, and save lives,” said Dr. William Weeks, Director of Health, Microsoft AI for Good Lab.

“At Slalom, we see the future of health as being the convergence of technology, data, and strategy to build better tomorrows for all,” said Brenda Young, managing director at Slalom. “CAIA demonstrates how collaboration between leading cancer centers and technology partners can unlock new insights and reshape the use of Data & AI to diagnose, treat, and prevent cancer. We look forward to our continued partnership as we pave the way for transformative breakthroughs in health.”

Media Contact:
Molly McElroy and Christina VerHeul
media@fredhutch.org
206-667-2210

About the Cancer AI Alliance (CAIA)

The Cancer AI Alliance (CAIA) is comprised of the nation’s top cancer centers with support from technology industry leaders. CAIA aims to accelerate cancer discovery and treatment. Since its founding in 2024, CAIA has secured $65M in financial and technical support. Through this unprecedented collaboration, CAIA launched the first scalable, multi-cloud federated learning platform for cancer research, which enables researchers to train AI models on diverse, multi-institutional clinical data while maintaining data security and privacy. By combining the collective knowledge of its members, CAIA is on a mission to redefine the cancer research landscape.

Dana-Farber Cancer Institute  

Dana-Farber Cancer Institute is one of the world’s leading centers of cancer research and treatment. Dana-Farber’s mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement and advocacy. Dana-Farber is a federally designated Comprehensive Cancer Center and a teaching affiliate of Harvard Medical School.

Dana-Farber is the only hospital nationwide with a top 3 U.S. News & World Report Best Cancer Hospital ranking in both adult and pediatric care.

As a global leader in oncology, Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world, offering more than 1,100 clinical trials. 

Fred Hutch Cancer Center

Fred Hutch Cancer Center unites individualized care and advanced research to provide the latest cancer treatment options while accelerating discoveries that prevent, treat and cure cancer and infectious diseases worldwide.

Based in Seattle, Fred Hutch is an independent, nonprofit organization and the only National Cancer Institute-designated cancer center in Washington. We have earned a global reputation for our track record of discoveries in cancer, infectious disease and basic research, including important advances in bone marrow transplantation, immunotherapy, HIV/AIDS prevention and COVID-19 vaccines. Fred Hutch operates eight clinical care sites that provide medical oncology, infusion, radiation, proton therapy and related services. Fred Hutch also serves as UW Medicine’s cancer program. 

Johns Hopkins University

As the nation’s first research university, Johns Hopkins’ mission is to foster cutting-edge research and innovation, to educate its students and cultivate their capacity for lifelong learning, and to bring thebenefits of discovery to the world through its 10 world-renowned schools, and numerous institutes and centers.

Sidney Kimmel Comprehensive Cancer Center
Since our founding more than 50 years ago, our medical pioneers led the way to understanding cancer through impactful research, developing novel therapies, and attending to the complex needs of patients. Our experts mapped the genomic blueprints for cancer, deciphered the epigenome, discovered ways to make the immune system fight cancer, eliminated the need for perfect matches in bone marrow transplant, pioneered life-saving surgeries, and brought proton therapy and other advanced technologies in radiation therapy.

Whiting School of Engineering
We advance data- and science-driven engineering discovery, innovation, and systems applications to help everyone live longer and healthier lives and empower communities and society to thrive even in extreme environments. With more than 26 research centers and institutes – including the Data Science and AI Institute – and through strong community, university, and industry partnerships, Hopkins Engineering is a driving force in the future of technology, health care, and engineering education.

Memorial Sloan Kettering Cancer Center

The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert care to patients of all ages. Informed by basic research done at our Sloan Kettering Institute, scientists across MSK collaborate to conduct innovative translational and clinical research that is driving a revolution in our understanding of cancer as a disease and improving the ability to prevent, diagnose, and treat it. MSK is dedicated to training the next generation of scientists and clinicians, who go on to pursue our mission at MSK and around the globe. One of the world’s most respected comprehensive centers devoted exclusively to cancer, we have been recognized as one of the top two cancer hospitals in the country by U.S. News & World Report for more than 30 years. www.mskcc.org

Contact Information

Christina VerHeul
Associate Vice President, Communications
media@fredhutch.org
(206) 667-2210

Molly McElroy
Sr. Communications Manager
mwmcelro@fredhutch.org
206-667-2210

SOURCE: Fred Hutch Cancer Center

View the original press release on ACCESS Newswire

Early Patient Feedback Points to Clearer Understanding of Results and Smoother Treatment Planning

GRAND RAPIDS, MICHIGAN / ACCESS Newswire / October 1, 2025 / Quintessence Psychiatry, a telepsychiatry practice led by Nona Kocher, MPH, MD, has adopted Mentavi Health‘s asynchronous Diagnostic Evaluation to offer patients a scientifically rigorous, accessible alternative to full neuropsychological testing. The Mentavi Diagnostic Evaluation is clinically validated (and now peer-reviewed and published in the The Journal of Clinical Psychiatry*) for the diagnosis of ADHD in adults.

Quintessence Psychiatry previously referred ADHD inquiries to external neuropsychology providers – a process that can involve weeks to months of waiting and hundreds of dollars in testing costs for a broad battery of tests many patients don’t need. Early experiences at Quintessence show patients can complete the self-directed evaluation at their convenience (often at home) and return to the clinic with a report reviewed by a licensed psychologist to guide treatment conversations.

“Mentavi gives my patients a focused, evidence-based ADHD evaluation at a price and speed they can actually use,” said Dr. Nona Kocher, psychiatrist and founder of Quintessence Psychiatry. “It adds rigor to my workflow and helps patients understand what the findings mean, so we can move forward with an informed plan rather than sending them into a lengthy outside testing queue.”

In the initial phase of adoption, three patients have completed the evaluation, with positive feedback on the clarity of the results and visuals. Patients typically review the Mentavi report with Dr. Kocher at a follow-up visit to discuss how ADHD symptoms may be affecting daily life and to consider therapy and/or medication options. “The report graphics make it easier for patients to grasp their results at a glance, which improves shared decision making,” Dr. Kocher added.

Beyond speed and accessibility, the Mentavi Diagnostic Evaluation integrates cleanly into Quintessence’s care model, which emphasizes applying modern, science-based methods – including, when appropriate, pharmacogenetic testing – to reduce trial and error in treatment selection.

“We are pleased that our validated diagnostic approach can serve Quintessence Psychiatry by removing barriers to timely access to care for their patients. This is what our approach was designed for,” said Keith Brophy, CEO of Mentavi Health.

“Clinicians like Dr. Kocher tell us Mentavi helps them triage ADHD inquiries efficiently and focus their time where it matters most – on individualized care,” said Mentavi Health Chief Medical Officer Barry K. Herman, M.D., MMM. “We’re pleased to support private practices with an evaluation that is clinically validated, rigorous, patient-friendly, and easy to fold into existing workflows.”

Quintessence intends to continue offering the Mentavi Diagnostic Evaluation for appropriate ADHD cases and to gather ongoing patient feedback to inform clinical workflows.

* Peer‑reviewed validation: Results of Mentavi’s diagnostic validation study were published in The Journal of Clinical Psychiatry on September 8, 2025 (J Clin Psychiatry 2025;86(3):25m15846; doi:10.4088/JCP.25m15846).

About Quintessence Psychiatry

Quintessence Psychiatry is a patient-centered telepsychiatry practice led by Nona Kocher, MD, offering comprehensive evaluations, medication management, and individualized care plans. The practice integrates modern, evidence-based methods to help patients move from assessment to actionable next steps. For more information, visit quintessencepsychiatry.com.

About Mentavi Health

Established as ADHD Online in 2018, Mentavi Health has evolved to encompass a broader range of mental health services. With the mission to make high-quality ADHD assessments accessible to all, Mentavi has grown to address not only ADHD but also the most common related mental health conditions. The nationwide Mentavi Diagnostic Evaluation and various treatment options showcase the company’s commitment to providing comprehensive, accessible, and compliant online mental health care, grounded in clinical validation and trust. For more information, visit mentavi.com.

Contact Information

Tim Cox
ZingPR for Mentavi
tim@zingpr.com

SOURCE: Mentavi Health

Related Images

View the original press release on ACCESS Newswire

HAYWARD, CALIFORNIA / ACCESS Newswire / October 1, 2025 / Biolog, Inc., a trusted leader in microbial identification and testing, today announced its new Foodborne Pathogen Testing Service, out of it’s Newark, Delaware location, expanding its portfolio to include ISO-certified molecular assays that safeguard food safety and support regulatory compliance for food producers of all sizes.

The new service delivers rapid, scientifically validated detection across various matrices for the five most common foodborne pathogens: E. coli O157 (including H7), Salmonella, Listeria monocytogenes, Campylobacter, and Cronobacter.

“We’ve heard from many of our customers in food manufacturing that they are under intense pressure to ensure safety while keeping production on track,” said Robert Wicke, CEO at Biolog. “As their trusted microbial testing expert, we are thrilled to be able to offer this new service that helps them protect their brands, avoid costly recalls, and stay ahead of evolving regulatory requirements.”

With 40+ years of microbial expertise, Biolog Lab Services delivers a best-in-class combination of speed and dependability in microbial testing services. Customers benefit from reliable results in as little as three days, backed by AOAC, AFNOR validations, and ISO 17025 certification, ensuring adherence to the strictest global standards. The service offers high sensitivity and specificity at a competitive price point, while being grounded in USDA-approved and FDA-endorsed molecular science.

Biolog’s strategic proximity to major agricultural hubs gives regional produce, beef, and poultry producers a critical edge. By offering certified results in days rather than weeks, Biolog enables these producers to stay compliant, reduce scrap costs, and make confident decisions faster.

Biolog’s expansion into foodborne pathogen testing reinforces its role as a comprehensive partner for microbial testing solutions, delivering the expertise, speed, and dependability food producers need.

To learn more about Foodborne Pathogen Testing, request a quote, or explore Biolog’s comprehensive microbial testing portfolio, please visit www.biolog.com.

About Biolog
Biolog has the tools, services, and support to provide comprehensive cellular characterization and multi-omic identification for thousands of bacteria, yeast, and fungal species. Our products enable the growth and phenotypic profiling of microbial and mammalian cells for a wide range of applications, including pre-reduced media and gloveless chambers that support culturing organisms under strictly anaerobic conditions. Learn more at biolog.com.

SOURCE: Biolog, Inc.

View the original press release on ACCESS Newswire

GUELPH, ON / ACCESS Newswire / October 1, 2025 / Six Star Travel, a boutique agency specializing in travel planning, has been awarded the 2026 Consumer Choice Award in the Travel Agencies category for Guelph. Known for its expertise, personalized service, and commitment to excellence, Six Star Travel has built a reputation as a trusted partner for travellers seeking exceptional experiences.

Founded by travel professional Steven A. Faehrmann, Six Star Travel creates customized solutions designed to meet the needs of discerning clients. The agency offers a full spectrum of services, including cruises, resorts, hotels, expedition travel, and bespoke tours.

“Our role is to simplify travel planning while elevating the experience,” says Steven Faehrmann. “We focus on details that matter, from carefully selected accommodations to unique excursions, ensuring every client enjoys a journey that is thoughtfully curated and stress-free.”

A Commitment to Value and Service

As a member of Ensemble, Six Star Travel leverages exclusive relationships with leading suppliers worldwide. This allows clients to benefit from added value such as complimentary room upgrades, shipboard credits, and private tours. While specializing in premium travel, the agency’s focus on maximizing value ensures high-quality service at competitive rates.

Recognition and Client Trust

This marks the third consecutive year that Six Star Travel has been recognized with the Consumer Choice Award, reflecting its consistent commitment to excellence. Its 5-star Google reviews further highlight the trust and appreciation expressed by clients. With nearly two decades of experience, Steven’s passion for travel has taken him to more than 51 countries and over 700 cities worldwide – knowledge he draws on to deliver unique insights and advantages to every client journey.

Trusted by the Community

Located in Guelph, Six Star Travel has earned the loyalty of its clients by prioritizing reliability, professionalism, and personalized care. The agency is committed to supporting travellers throughout their journey – from consultation and booking to assistance during travel and follow-up upon return. Clients consistently commend the agency for its attention to detail, proactive problem-solving, and ability to anticipate needs. This dedication has helped Six Star Travel build lasting relationships with both new and returning customers in the Guelph region.

“Our success is grounded in the trust of our clients,” adds Faehrmann. “Receiving this recognition is an honour and a reflection of the service standard we strive to uphold every day.”

About Six Star Travel
Six Star Travel is a boutique travel agency based in Guelph, Ontario. Led by founder Steven A. Faehrmann, the agency provides a full range of services including cruises, resorts, tours, and expedition travel. With a focus on integrity, value, and client satisfaction, Six Star Travel delivers exceptional service and unforgettable journeys. To learn more, visit www.sixstartravel.ca.

About Consumer Choice Award
Since 1987, Consumer Choice Award has been recognizing and promoting business excellence across North America. Through a rigorous selection process, only the most outstanding businesses in each category earn this prestigious recognition. Learn more at www.ccaward.com

Contact Information:
Sumi Saleh
Communications Manager
ssaleh@ccaward.com

SOURCE: Consumer Choice Award

View the original press release on ACCESS Newswire

LOS ANGELES, CALIFORNIA / ACCESS Newswire / October 1, 2025 / On National Coming Out Day, Gay Ad Network, the leading LGBTQ+ digital advertising platform, today announced the launch of a groundbreaking programmatic Digital Out-of-Home (DOOH) advertising solution – the first of its kind designed exclusively to reach LGBTQ+ audiences in the physical world.

This new offering is powered by Basis Technologies and provides seamless access to premium DOOH inventory through integrations with Vistar Media and Place Exchange. Advertisers can reach LGBTQ-focused audiences across more than 740,000 digital screens nationwide. Placements range from iconic neighborhoods such as West Hollywood, Chelsea, the Castro, and South Beach to in-store displays at retailers, gyms, airports, and nightlife venues

“Digital Out-of-Home is one of the fastest-growing channels in advertising, and LGBTQ+ audiences are at the cultural and economic forefront,” said Mark Elderkin, CEO of Gay Ad Network. “By combining advanced targeting with community-specific placements, we’re making it easier than ever for brands to reach LGBTQ+ consumers in the spaces where they live, work, shop, and celebrate.”

“Basis is proud to support Gay Ad Network’s launch of the first LGBTQ+ focused programmatic DOOH solution,” said Jim Zabel, VP Client Development at Basis Technologies. “This collaboration gives advertisers seamless access to premium digital out-of-home inventory, while also enabling unified, omnichannel campaign management. It’s a powerful example of how programmatic technology can expand visibility, foster authentic inclusion, and drive measurable results.”

Key Features of the offering include:

Exclusive LGBTQ+ Reach: Screens placed in LGBTQ-centric neighborhoods, nightlife venues, gyms, and retail locations.

Event Activation: High-impact visibility during Pride parades, queer film and music festivals, and cultural celebrations.

Omnichannel Extension: Combine DOOH exposure with mobile retargeting to reinforce messaging after audiences leave the venue.

Advanced Measurement: Track impressions, foot traffic lift, online conversions, and brand impact studies with full transparency.

The offering gives brands the opportunity to not only capture attention in high-traffic environments but also to demonstrate authentic inclusion by showing up in the spaces most meaningful to LGBTQ+ communities.

“On National Coming Out Day, we’re reminded that visibility is power,” added Elderkin. “By showing up in real-world environments, brands are making a statement of support while driving measurable business results.”

Gay Ad Network’s LGBTQ+ DOOH solution is available immediately for advertisers across all U.S. markets.

About Gay Ad Network
Gay Ad Network is the leading digital media platform connecting advertisers with LGBTQ+ consumers through premium content, data-driven targeting, and innovative ad solutions. Committed to diversity, inclusion, and brand authenticity, Gay Ad Network helps brands engage with LGBTQ+ audiences in ways that are impactful, measurable, and culturally relevant.

SOURCE: Gay Ad Network

View the original press release on ACCESS Newswire

HESPERIA, CA / ACCESS Newswire / September 30, 2025 / 5E Advanced Materials, Inc. (“5E” or the “Company”) (Nasdaq:FEAM)(ASX:5EA), a development stage company focused on becoming a vertically integrated global leader and supplier of refined borates and advanced boron derivative materials, hosted its Fiscal Year 2025 year-end conference call yesterday.

During the call, the Company’s Chief Executive Officer, Paul Weibel, highlighted the transition from development to commercial readiness, underscoring achievements that position 5E as the future cornerstone in the global boron supply chain:

• Robust Project Economics – The recently published SK-1300 Preliminary Feasibility Study (PFS) validated Phase 1 of the Fort Cady project with a pre-tax NPV7 of US$725 million, 19.2% IRR, and a 39.5-year life of mine. The study estimates ~US$3.7 billion in pre-tax free cash flow and outlines a scalable operation supported by 5.4 million short tons of boric acid reserves.

• Commercial Traction Expands – 14 customers have now successfully qualified 5E’s high-purity boric acid across industries including specialty glass, fiberglass, agriculture, defense, and chemicals.

• Full-scale Product Testing -Following a successful logistics and furnace trial, 5E is ready to complete full-scale product testing with a Tier-1 specialty glass manufacturer. Twenty tons of high-quality boric acid are produced, and shipment is imminent. Additional large LCD glass manufacturers are already queued for similar testing, demonstrating strong near-term commercial pull.

• Financing Pathway Strengthened – The Company secured a non-binding LOI from U.S. EXIM Bank for a potential US$285 million debt facility. In parallel, 5E is ready to apply for EXIM’s Engineering Multiplier program targeting US$8.5-10 million to fund FEED engineering.

• Critical Minerals List – The United States Geological Survey (USGS) recently closed its public comment period on the draft critical minerals list. Per the Federal Register, the Company, along with eight other groups, submitted comment letters in favor of adding boron to the list.

• Roadmap to Final Investment Decision (FID) – With early FEED activities underway, 5E remains on track to reach FID by mid-2026. Upcoming catalysts include completion of full-scale customer tests, securing offtake agreements, advancing project financing, and the potential inclusion of boron on the U.S. Geological Survey’s Critical Minerals List.

Mr. Weibel emphasized the strategic importance of boron for U.S. supply chain resilience, particularly as global producers face cost pressures and restructuring. “Fiscal 2025 marked a true inflection year for 5E,” said Mr. Weibel. “We are building a U.S.-based boron supply chain at a time when demand is rising sharply, supply shortfalls are projected as early as 2026, and the market needs a new and reliable domestic producer.”

A replay of the Fiscal Year 2025 earnings call is now available at the following link HERE.

About 5E Advanced Materials, Inc.

5E Advanced Materials, Inc. (Nasdaq:FEAM)(ASX:5EA) is focused on becoming a vertically integrated global leader and supplier of refined borates and advanced boron materials, complemented by calcium-based co-products, and potentially other by-products such as lithium carbonate. The Company’s mission is to become a supplier of these critical materials to industries addressing global decarbonization, energy independence, food, national security, and the defense sector. The Company believes factors such as government regulation and incentives focused on domestic manufacturing and supply chains and capital investments across industries will drive demand for end-use applications like solar and wind energy infrastructure, neodymium-ferro-boron magnets, defense applications, lithium-ion batteries, and other critical material applications. The business is based on the Company’s large domestic boron resource, which is located in Southern California and designated as Critical Infrastructure by the Department of Homeland Security’s Cybersecurity and Infrastructure Security Agency.

Forward Looking Statements

Statements in this press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, and include, but are not limited to, statements regarding the Company’s ability to progress full-scale product testing, advance the qualification of our boric acid with customers, enter into offtake agreements, receive any proceeds under any of EXIM’s loan programs, boron’s potential to be placed on the USGS critical minerals list, achieve key milestones on the path toward a potential Final Investment Decision, and become a vertically integrated global leader in borates and advanced boron materials. Any forward-looking statements are based on 5E’s current expectations, forecasts, and assumptions and are subject to a number of risks and uncertainties that could cause actual outcomes and results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, statements regarding the Company’s ability to progress full-scale product testing, advance the qualification of our boric acid with customers, enter into long-term supply agreements, receive any proceeds under any of EXIM’s loan programs, boron’s potential to be placed on the USGS critical minerals list, achieve key milestones on the path toward a potential Final Investment Decision, and become a vertically integrated global leader in borates and advanced boron materials. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled ‘Risk Factors’ in 5E’s most recent Annual Report on Form 10-K and its other reports filed with the SEC. Forward-looking statements contained in this announcement are based on information available to 5E as of the date hereof and are made only as of the date of this release. 5E undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing 5E’s views as of any date subsequent to the date of this press release. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of 5E.

For further information contact:
Michael MacMillan or Paola Ashton
PRA Communications
team@pracommunications.com
Ph: +1 (604) 681-1407

SOURCE: 5E Advanced Materials, Inc.

View the original press release on ACCESS Newswire

HOUSTON, TX / ACCESS Newswire / September 30, 2025 / EON Resources Inc. (NYSE American:EONR) (“EON” or the “Company”) is an independent upstream energy company with 20,000 leasehold acres in the Permian Basin. The fields have a total of 750 producing and injection wells producing over 1,000 barrels of oil per day. Today, the Company posted an investor deck regarding the September 9, 2025 Funding and the Farmout of San Andres rights for the horizontal drilling program to the Company’s website: https://www.eon-r.com/presentations.

About EON Resources Inc.
EON is an independent upstream energy company focused on maximizing total returns to its shareholders through the development of onshore oil and natural gas properties in a diversified portfolio of long-life producing oil and natural gas properties and other energy holdings. EON’s approach is to build an energy company through acquisition and through selective development of its properties. Class A Common Stock of EON trades on the NYSE American Stock Exchange under the symbol of “ EONR” and the Company’s public warrants trade under the symbol of “ EONRWS”. For more information on the Company, please visit the EON website.

About the Grayburg-Jackson Field Property
Our Grayburg-Jackson Field (“GJF”) is primarily a waterflood property located on the Northwest Shelf of the Permian Basin in Eddy County, New Mexico. The GJF comprises of 13,700 contiguous leasehold acres with 342 producing wells, 207 injection wells and 1 water source well for a total of 550 wells. Leasehold rights include the Seven Rivers, Queen, Grayburg and San Andres intervals that range from as shallow as 1,500 feet to 4,000 feet in depth. The December 2024 reserve report from our third-party engineer, Haas and Cobb Petroleum Consultants, LLC, estimates proven reserves of approximately 14.0 million barrels of oil and 2.8 billion cubic feet of natural gas. The mapped original-oil-in-place (“OOIP”) is approximately 956 million barrels of oil. Primary production is currently from the Seven Rivers formation. In addition to proven reserves, the Company believes it may access an additional 34 million barrels of oil by adding perforations in the Grayburg and San Andres formations, plus another 40 million barrels from a horizontal drilling program in the San Andres. More information on the property can be located on the Grayburg-Jackson Field page of our website.

About the South Justis Field Property
The South Justis Field (“SJF”) is a carbonate reservoir similar to the rest of the Permian, and is located in Lea County, New Mexico approximately 100 miles from the GJF. The SJF is comprised of 5,360 contiguous acres containing 208 total producing and injection wells with well spacing of 50 acres. The producing formations include the Glorietta, Blinebry, Tubb, Drinkard and Fusselman intervals that range from 5,000 feet to 7,000 feet in depth. The original-oil-in-place (“OOIP”) is approximately 207 million barrels of oil. More information on the property can be located on the South Justis Field page of our website.

Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to differ materially from what is expected. Words such as “expects,” “believes,” “anticipates,” “intends,” “estimates,” “seeks,” “may,” “might,” “plan,” “possible,” “should” and variations and similar words and expressions are intended to identify such forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements relate to future events or future results, based on currently available information and reflect the Company’s management’s current beliefs. A number of factors could cause actual events or results to differ materially from the events and results discussed in the forward-looking statements. Important factors – including the availability of funds, the results of financing efforts and the risks relating to our business – that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on EDGAR (see www.edgar-online.com) and with the Securities and Exchange Commission (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Investor Relations
Michael J. Porter, President
PORTER, LEVAY & ROSE, INC.
mike@plrinvest.com

SOURCE: EON Resources Inc.

View the original press release on ACCESS Newswire

SOUTHLAKE, TX / ACCESS Newswire / September 30, 2025 / Allied OMS, the nation’s leading doctor-owned and doctor-led management services organization (MSO) for oral and maxillofacial surgeons, today announced the appointment of Bill Murray as Chief Financial Officer.

Bill brings more than two decades of experience guiding healthcare and technology companies through periods of rapid growth and transformation. He has led private equity-backed organizations, raised significant capital to fund expansion, and built scalable financial and operational systems. His background in healthcare services, analytics, and technology positions him to help Allied strengthen its platform and accelerate its next phase of growth.

According to Dan Hosler, CEO of Allied OMS, Bill’s experience aligns perfectly with the company’s trajectory: “Bill’s record of building and scaling high-growth healthcare businesses is what we need as Allied OMS accelerates its expansion nationwide. His ability to align financial strategy with operational execution will help us deliver on our mission of creating the doctor-led partnership for the future of oral surgery.”

Bill noted that Allied OMS’s distinctive structure was a key factor in his decision to join: “I was drawn to Allied OMS because of its unique doctor-led model and its focus on alignment around patient outcomes. Too often, financial targets and clinical priorities can work against each other – here, they move in lockstep. I’m excited to help drive growth while ensuring our surgeons have the support, resources, and autonomy they need to thrive.”

Dr. Jonathon Jundt, Co-Founder and Chief Medical Officer at Allied OMS, added: “Growth only matters if it translates into real benefits for surgeons and patients. Bill’s leadership will ensure we continue investing in the resources, support, and infrastructure that allow our doctors to practice the way they want while expanding access to care.”

Bill’s appointment follows Allied OMS’s recent minority investment from 65 Equity Partners, which provides additional capital to accelerate the platform’s growth. With Bill’s financial leadership, Allied is poised to advance its strategy – partnering with like-minded oral and maxillofacial surgeons who want to shape the future of the specialty, recruiting residents and associates into careers they love, opening de novo locations to expand patient care, and helping existing practices maximize their growth potential. His expertise will ensure these initiatives are executed sustainably while strengthening the only doctor-led oral surgery platform in the country.

About Allied OMS

Allied OMS is a doctor-owned, doctor-led, and doctor-governed MSO that partners with oral and maxillofacial surgery practices across the U.S. Combining the autonomy of private practice with the scale and sophistication of institutional support, Allied OMS empowers surgeons to lead the future of their specialty. The company currently supports surgeons in 50+ locations and maintains doctor leadership across all major committees and its Board of Directors. Learn more at www.alliedoms.com.

###

Sara Tumen Weinberg
Chief Marketing Officer
Allied OMS
sweinberg@alliedoms.com

SOURCE: Allied OMS

View the original press release on ACCESS Newswire

WASHINGTON, D.C. / ACCESS Newswire / September 30, 2025 / AGS Health, a leading provider of tech-enabled revenue cycle management (RCM) solutions and a strategic growth partner to healthcare providers across the U.S., has been named a recipient of the UiPath AI25 Award for its pioneering use of agentic AI automation to assist healthcare providers in managing the rising rate of costly healthcare claim denials.

Through their Denial Management Agents, AGS Health helps healthcare providers to reduce preventable denials, expedite appeals, and improve clean claim rates, projecting gains of up to 6 percent in clean claims and 20-26 percent faster handling times. This achievement, which marks the company’s second consecutive UiPath AI25 Award following recognition in 2024, reflects its innovative hybrid workforce model where UiPath bots, AI agents, and skilled human specialists work seamlessly across critical RCM workflows such as prior authorization validation, denial classification and follow-up, medical necessity rejections, and timely filing checks. In this model, AI agents handle analysis and reasoning, bots manage routine tasks, and human experts oversee high-risk cases, audit, and quality control, ensuring efficiency and accuracy.

“These winners are breaking new ground with agentic automation. They’re orchestrating people, AI, and robots to transform processes and deliver measurable impact,” said Graham Sheldon, Chief Product Officer at UiPath and Executive Sponsor for the AI25 Awards. “We’re proud to recognize their achievements and excited to see how they continue pushing the boundaries of what’s possible.”

The UiPath AI25 Awards spotlight the 25 most innovative implementations of the UiPath Platform^™ for agentic automation. Winners demonstrate measurable ROI, productivity gains, and transformative business impact by orchestrating agents, bots, and people. Recognition spans both proven outcomes and promising early-stage initiatives that showcase the future of automation.

“AGS Health has embraced the healthcare industry’s shift toward autonomous operations while keeping human expertise at the center,” says Patrice Wolfe, CEO of AGS Health. “Our hybrid intelligence approach merges the speed and scalability of AI agents with the judgment and empathy of skilled professionals. This recognition by UiPath reaffirms our focus on building smarter, faster, and more autonomous processes that increase accuracy, efficiency, and financial performance with expert human oversight.

Adds AGS Health CIO Thomas Thatapudi, “Agentic automation enables us to deliver faster, more accurate RCM services, which is crucial for healthcare providers navigating cost pressures and rising claim volumes. By automating high-volume, error-prone tasks, we’re helping reduce denials and improve first-pass rates, directly enhancing our customers’ cash flow.”

About AGS Health

AGS Health is more than a revenue cycle management company-we’re a strategic partner for growth. Our distinctive methodology blends award-winning services with intelligent automation and high-touch customer support to deliver peak end-to-end revenue cycle performance and an empowering patient financial experience.

We employ a team of 15,000 highly trained and college-educated RCM experts who directly support customers spanning a variety of care settings and specialties, including nearly half of the 20 most prominent U.S. hospitals and 40% of the nation’s 10 largest health systems. Our thoughtfully crafted RCM solutions deliver measurable revenue growth and retention, enabling customers to achieve the revenue to realize their vision.

# # #

Media Contact:

Liz Goar, NPC Creative Services
liz@npccs.com

SOURCE: AGS Health

View the original press release on ACCESS Newswire

LACONIA, NEW HAMPSHIRE / ACCESS Newswire / September 30, 2025 / ePropelled, a leading innovator in high-efficiency electric propulsion for unmanned vehicles, has reached a major milestone with 47 granted and pending patents across 13 product families. The company’s expanding IP portfolio reflects breakthrough technologies for electric mobility across air, land, sea, and industrial sectors.

“This achievement shows how quickly our team is turning ideas into real-world solutions,” said Nick Grewal, ePropelled Founder, Chairman & CEO. “We’re focused on creating cleaner, lighter, and more affordable electric propulsion for unmanned vehicles, in the air, on the ground and in the sea, while protecting the innovations that make it possible.”

Recent milestones include:

• US12323039B2: A newly granted US patent for an advanced uncrewed aerial vehicle (UAV) generator design (June 2025)

• EP3973620A1: This European patent application relates to an advanced cooling of a UAV generator, which is scheduled to be granted in October 2025

• Design patents: Covering electric machines with integrated cooling and drive circuits

ePropelled continues to develop and protect multiple core concepts behind its dynamic torque switching (eDTS™) technology and hybrid electric-jet systems, aimed at next-generation aircraft and electric vertical take-off and landing aircraft (eVTOL).

“Every patent begins with solving a real customer problem,” said Dr. Nabeel Shirazee, ePropelled Global CTO. “Our engineers focus on ideas that lower energy use, increase range, or streamline manufacturing for our partners.”

ePropelled’s growing patent portfolio underscores its leadership in powering the future of electrification.

SOURCE: ePropelled, Inc.

View the original press release on ACCESS Newswire